Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer. The intensity and setting of the follow-up was tailored to the needs and individual risk of the patients. The patients themselves took blood samples and looked at the results. In case of an unclear or 'wrong' result, the patients themselves contacted the hospital for follow-up steps.
More personal and more affordable
This has been an affordably better project, in which patients organise their own follow-up after 1 year, with the help of the health insurance company. In the Radboudumc this has saved 118 patients in one year about 22,000 euros and will possibly save between 5-10 million euros on an annual basis in the Netherlands. Most patients were very satisfied with this new way of follow-up and about 70% did not seek contact with the hospital and arranged the follow-up themselves.
Expand and record
Surgeon Hans de Wilt and his colleagues from the Department of Surgery and the Amsterdam UMC received a ZonMW subsidy of € 903,315 to develop a protocol for this new more personal and cost-effective form of follow-up. The study will consist of two parts, in which the protocol as applied in the Radboudumc will be introduced in four other hospitals in the Netherlands. In addition, the researchers at the Amsterdam UMC will investigate whether there are patients who may need a different form of follow-up. The expectation is that this will also make it possible to introduce an optimal follow-up schedule per patient in other hospitals in the Netherlands afterwards.
Related news items
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more
ERC Proof of Concept grant received by Ronald van Rij30 July 2020
Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.read more
Hypatia fellowship Call is open30 July 2020
The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.read more
Mihai Netea and colleagues published two papers back-to-back in The Journal of Clinical Investigation.29 July 2020
These back-to-back articles investigated the effect of BCG vaccination on trained immunity. The first article shows that BCG vaccination inhibits systemic inflammation, depending on gender. The second article demonstrates that the circadian rhythm influences the induction of trained immunity.read more
Genetic mutation reveals how coronavirus strikes TLR7 plays essential role in disease process28 July 2020
''Does a congenital immune defect play an important role in the defense against Coronavirus?'' This was published by Cas van der Made, Frank van der Veerdonk and Alexander Hoischen.read more